Introduction {#Sec1}
============

Renal cell carcinoma (RCC) is the third most common urologic cancer in the world, making up roughly 3% of all human cancers^[@CR1]^. Studies have shown that 20\~30% RCC recur after surgical treatment, thus highlighting the importance of: i) using prognosticators (eg, pathological staging) when developing a treatment plan and ii) close monitoring during and following treatment^[@CR2]--[@CR5]^. The 2002 RCC Tumor-Node-Metastasis (TNM) staging system defined T3 RCC as a tumor that extends to fat, adrenal or major vein. In 2009 however, this system was updated to better differentiate and improve prognosis of T3 tumors^[@CR6]--[@CR8]^. In the 2009 version, renal vein invasion was down-staged from T3b to T3a and adrenal invasion was up-staged from T3a to T4 or M1^[@CR6]^.

In the current staging system, T3a RCC is defined as a tumor with extra-renal fat invasion (EFI) (perinephric or sinus fat invasion) and renal venous invasion (RVI) (renal vein or its segmental muscle containing branch)^[@CR9]^. The limited data available comparing the prognostic significance of EFI and/or RVI are inconsistent^[@CR10],[@CR11]^. For instance, some studies have suggest a significant impact of RVI on clinical outcome, while others have reported no prognostic value to the presence of tumor thrombus^[@CR12]^. Other studies show that RCC with both EFI and RVI have higher recurrence rates than those with only EFI or RVI^[@CR10]^.

Currently, a T3a RCC tumor may have EFI and/or RVI and the prognostic significance of these characteristics is unclear. We hypothesize that T3 tumors with EFI and RVI are more aggressive than those with only EFI or RVI and have designed the current research study to compare the impact of these features in non-metastatic T3a tumors (ie, prognosis, survival).

Materials and Methods {#Sec2}
=====================

An approval of this study was obtained from institutional review board approval (B-1712/381-108, and written informed consent was acquired from all patients before the inclusion to the research.

Patient selection {#Sec3}
-----------------

After receiving institutional review board approval, we reviewed the data of all patients (n = 4,483) who underwent a partial or radical nephrectomy for RCC between February 1988 and December 2015 from two tertiary hospital (Seoul National University Hospital and Seoul National University Bundang Hospital). Among them, we identified 211 patients with T3aN0M0 RCC for this analysis.

Data collection protocol {#Sec4}
------------------------

Postoperative pathologic tumor stages and grades were determined in accordance with the seventh AJCC TNM staging^[@CR13]^ and Fuhrman grading system^[@CR14]^, respectively. Histological subtypes of RCC were assigned in accordance with the WHO classification system^[@CR15]^. We evaluated the following clinical and pathologic features: age at surgery, gender, body mass index, Eastern Cooperative Oncology Group performance (ECOG) performance status, surgery type (partial nephrectomy \[PN\] or radical nephrectomy \[RN\]), tumor location, tumor size, histologic subtype (clear cell, papillary, chromophobe and unclassified), Fuhrman nuclear grade, capsular invasion, presence of necrosis, angiolymphatic invasion, perineural invasion and sarcomatoid differentiation. Additionally, T3a tumors were classified as: i) isolated EFI, isolated RVI, or iii) EFI and RVI.

Follow up protocol {#Sec5}
------------------

After nephrectomy, all patients were followed up on according to the SNU protocol. Symptom assessments, routine blood tests, chest x-rays and kidney/bladder Computed tomography (CT) scans were conducted every 3 months for the first 2 years. Following year 2, the same battery of tests were conducted every 6 months for 2 years followed by annual follow ups as necessary.

Statistical analysis {#Sec6}
--------------------

Comparisons were conducted across the T3a patient classifications (ie, EFI, RVI, and EFI + RVI). Another group analysis was performed according to the number of cause of pT3a (ie, isolated EFI or RVI, and EFI + RVI). Analyses were performed using SPSS for Windows, version 22.0 (SPSS Inc., Chicago,IL, USA). Fisher's exact and Pearson chi-squared tests were performed to compare clinical and pathological features among groups. Differences in variables with a continuous distribution across dichotomous categories were assessed using the Mann --Whitney U -test. A P value of \<0.05 was considered statistically significant.

Recurrence was defined as radiologically verified metastasis or local disease recurrence during the study period. Recurrence-free survival (RFS) was defined as the interval between the primary surgery and the last follow-up visit and the absence of disease recurrence or progression. Cancer-specific survival (CSS) was defined as the interval between the primary surgery and the last follow-up visit or RCC related death. The RFS and CSS in each group were estimated using Kaplan-Meier methods and the log-rank test was applied to compare survival curves. Univariate and Multivariate Cox proportional hazard models were used to verify predictors of RFS and CSS.

Results {#Sec7}
=======

Baseline characteristics of pT3a RCC patients {#Sec8}
---------------------------------------------

The clinical and pathological characteristics of 211 T3aN0M0 RCC patients who underwent nephrectomy are summarized in Table [1](#Tab1){ref-type="table"}. This study included 158 male patients (74.9%) and 53 female patients (25.1%). The median age (IQR) was 60 years old (52--69), mean BMI (IQR) was 23.9 (22.3--26.2) and most patients had ECOG performance status 0--1 (95.3%). Among 211 patients, 26 patients (12.3%) underwent PN. Median tumor size (IQR) was 6.8 centimeter (4.9--9.4), and 81.5% of tumors were classified as clear cell type. EFI was present in 173 patients (82.0%) and RVI was present in 84 (39.8%); 47 patients had EFI and RVI (23.3%). Total of 124 (58.8%) patients had only EFI and 40 (19.0%) patients had only RVI as cause of pT3a, respectively. The comparison of baseline characteristics according to groups were shown in Table [1](#Tab1){ref-type="table"}.Table 1Clinical and pathological characteristics of the patients with pT3a renal cell carcinoma according to cause of pathologic T3a.VariablesTotalEFI onlyRVI onlyEFI + RVIp-valueNo. patients2111244047Median age (year)(IQR)60.0 (52--69)58.5 (50.0--69.0)62.8 (54.0--71.0)62.7 (56.0--69.0)0.041Female (%)53 (25.1)30 (24.2)13 (32.5)10 (21.3)0.509Median body mass index (kg/m^2^)(IQR)23.9 (22.3--26.2)24.4 (22.6--26.3)24.5 (22.1--26.3)24.0 (21.7--26.2)0.690ECOG performance status (%)0.475   0--1201 (95.3)120 (96.8)38 (95.0)44 (93.6)   2--310 (4.7)4 (3.2)2 (5.0)3 (6.4)Partial nephrectomy (%)26 (12.3)22 (17.7)1 (2.5)3 (6.3)0.012Median pathologic tumor diameter (cm)(IQR)6.8 (4.9--9.4)6.5 (4.5--9.5)7.2 (4.5--9.1)7.0 (5.0--9.4)0.600Histological type (%)0.489   Clear cell172 (81.5)100 (80.6)34 (85.0)38 (80.9)   Papillary15 (7.1)10 (8.1)1 (2.5)4 (8.5)   Chromophobe18 (8.5)11 (8.9)3 (7.5)4 (8.5)   Others6 (2.9)3 (2.4)2 (5.0)1 (2.1)Fuhrman grade (%)0.195   1--245 (20.3)31 (25.0)4 (10.0)9 (19.1)   3--4166 (78.7)93 (75.0)36 (90.0)38 (80.9)Positive surgical margin (%)4 (1.9)2 (1.6)1 (2.5)1 (2.1)0.939Capsular invasion (%)152 (72.0)102 (82.3)12 (30.0)38 (80.9)\<0.001Necrosis (%)103 (48.8)59 (47.6)18 (45.0)26 (55.3)0.541Angiolymphatic invasion (%)33 (15.6)10 (8.1)9 (22.5)14 (29.8)0.001Perineural invasion (%)6 (2.8)3 (2.4)1 (2.5)2 (4.3)0.804Sarcomatoid differentiaton (%)26 (12.3)11 (8.9)3 (7.5)12 (25.5)0.007IQR; interquartile range, ECOG; Eastern Cooperative Oncology Group, EFI; isolated extracapsular fat invasion, RVI; isolated renal venous invasion.

Recurrence-free survival {#Sec9}
------------------------

During a mean follow-up of 38.8 months (median 26.0 months), radiologic recurrence was observed in 42 patients (19.9%). The site of recurrence was recorded as renal fossa (28/42, 66.6%), lymph node (8/42, 19.0%) and lung (4/42. 9.5%). RFS was significantly lower in EFI + RVI group than either EFI only or RVI only groups (Fig. [1A](#Fig1){ref-type="fig"}, log rank test = 0.008 or 0.010, respectively). According to the number of parameters leading to T3a classification, which Group B (EFI + RVI) had a significantly lower RFS rate than Group A (EFI only + RVI only) (Fig. [1B](#Fig1){ref-type="fig"}, p = 0.002). Seven-year RFS rates were calculated as 57.8% in Group A and 26.4% in Group B.Figure 1Recurrence free survival of 211 patients with T3aN0M0 renal cell carcinoma patients according to presence of extrarenal fat invasion (EFI) and/or renal venous invasion (RVI). Comparison by Kaplan-meier analysis showed each group (EFI vs. RVI vs. both) (**A**), comparison by the number of pathologis (EFI/RVI) -- isolated EFI or RVI vs. both group (**B**).

As shown in Table [2](#Tab2){ref-type="table"}, sex, tumor size, tumor necrosis, perineural invasion, angiolymphatic invasion, sarcomatoid differentiation and having both EFI and RVI (Group B) were significant factors in univariate Cox proportional hazard analysis and predictive of tumor recurrence. Using a multivariate analysis, sex, tumor size, tumor necrosis, and having both EFI and RVI (Group B) were shown to be significant factors.Table 2Uni- and Multi-variable Cox-regression analyses on recurrence free survival.VariablesHR (95% CI)p-valueHR (95%CI)p valueUnivariate analysisMultivariate analysisAge1.005 (0.984--1.027)0.650Female1.905 (1.131--3.207)0.0152.222 (1.291--3.825)0.003Body mass index0.929 (0.851--1.015)0.101ECOG performance status2.326 (0.937--6.463)0.105Tumor diameter1.163 (1.103--1.227)\<0.0011.107 (1.047--1.170)\<0.001Surgical methods (RN vs PN)0.634 (0.273--1.474)0.290Surgical margin positive0.955 (0.475--1.919)0.897Histologic type (clear cell vs.)1.272 (0.700--2.313)0.430Fuhrman grade (1--2 vs 3--4)1.624 (0.859--3.072)0.136Extra-renal fat invasion5.154 (4.264--6.230)\<0.001Renal venous invasion6.175 (5.050--7.550)\<0.001pT3a factor (2 vs 1)2.254 (1.319--3.850)0.0031.961 (1.059--3.632)0.032Capsular invasion1.099 (0.624--1.935)0.744Necrosis3.100 (2.777--3.461)\<0.0013.163 (1.760--5.684)\<0.001Perineural invasion7.681 (4.091--14.420)\<0.0011.795 (0.487--6.624)0.380Angiolymphatic invasion6.356 (5.004--8.074)\<0.0011.923 (0.985--3.753)0.055Sarcomatoid differentiation1.412 (1.305--1.529)\<0.0011.409 (0.694--2.863)0.343HR; hazard ratio, CI; confidence interval, ECOG; Eastern Cooperative Oncology Group, RN; radical nephrectomy, PN; partial nephrectomy.

Cancer-specific survival {#Sec10}
------------------------

During follow-up, 23 patients died due to RCC. CSS free survival was lower in the EFI + RVI group than either EFI-only or RVI-only group, however this difference was not statistically significant (Fig. [2](#Fig2){ref-type="fig"}, log rank test = 0.625, 0.882, respectively). Using a multivariate Cox proportional hazard analysis, tumor size was shown to be a significant factor in determining CSS among T3a RCC patients who underwent nephrectomy (HR = 1.133, 95% CI: 1.040--1.234, p = 0.004) (Table [3](#Tab3){ref-type="table"}). Another factors (positive surgical margin and presence of tumor necrosis) were significant factors to predict cancer specific survival (HR = 19.864, p \< 0.001 and HR = 4.238, p = 0.025, respectively).Figure 2Cancer specific survival of 211 patients with T3aN0M0 renal cell carcinoma patients according to presence of extrarenal fat invasion (EFI) and/or renal venous invasion (RVI). Comparison by Kaplan-meier analysis showed each group (EFI vs. RVI vs. both) (**A**), comparison by the number of pathologis (EFI/RVI) -- isolated EFI or RVI vs. both group (**B**).Table 3Uni- and Multi-variable Cox-regression analyses on cancer specific survival.VariablesHR (95% CI)p-valueHR (95%CI)p valueUnivariate analysisMultivariate analysisAge0.980(0.945--1.017)0.290Female1.037 (0.403--2.669)0.940Body mass index0.973 (0.841--1.125)0.708ECOG performance status2.660(0.610--11.594)0.193Tumor diameter1.169 (1.092--1.252)\<0.0011.133 (1.040--1.234)0.004Surgical methods (RN vs PN)0.368 (0.048--2.748)0.329Surgical margin positive7.784 (1.758--34.457)0.00719.864 (3.803--103.749)\<0.001Histologic type (clear cell vs.)1.346 (0.492--3.684)0.563Fuhrman grade (1--2 vs 3--4)2.216 (0.736--6.672)0.157Extra-renal fat invasion1.033 (0.232--4.605)0.966Renal vein invasion1.701 (0.960--4.197)0.249pT3a factor (2 vs 1)1.901 (0.735--4.918)0.1851.907 (1.107--12.301)0.201Capsular invasion0.525 (0.224--1.229)0.138Necrosis4.760 (1.601--14.148)0.0054.238 (1.201--14.957)0.025Angiolymphatic invasion2.166 (0.777--6.035)0.139Sarcomatoid differentiation3.778 (1.232--11.583)0.0201.580 (0.434--5.747)0.487HR; hazard ratio, CI; confidence interval, ECOG; Eastern Cooperative Oncology Group, RN; radical nephrectomy, PN; partial nephrectomy.

Discussion {#Sec11}
==========

In this analysis, we reviewed 211 T3aN0M0 RCC patients who underwent surgical treatment, and stratified patients according to the cause of their RCC classification as T3a; the 173 EFI (82.0%) and 84 RVI (39.8%) patients had similar RFS rates during a median follow-up of 26.0 months. However, patients with both EFI and RVI (n = 47, 23.3%) had a significantly lower RFS rate than patients who had only one factor. Despite of no significance to CSS, the patients who had EFI and RVI had more aggressive feature among T3a RCC patients.

Da Costa *et al*.^[@CR10]^ who reported similar results to ours stratified 46 T3a RCC patients into one of 3 groups: i) EFI only (24 \[52.1%\]), ii) RVI only (11 \[23.9%\]), and iii) EFI and RVI (11 \[23.9%\]). According to their study, patients with both pathologies had poorer RFS rate (roughly 22%) than patients with only one factor. In our study, using larger cohorts, patients with both pathologies had a PFS of 26.4% at 7 years.

According to the current TNM staging system, EFI and RVI can each lead to inclusion in same stage -- (T3a) regardless of whether one or both of these pathologies (EFI or RVI) are present. However, several previous studies have shown that patients with EFI and RVI had poorer outcomes than those with only one (EFI or RVI)^[@CR10],[@CR16]--[@CR18]^. A recent European multi-center study^[@CR17]^, validated the latest edition of the TNM (2009), evaluating 503 cases of T3a stage RCC and noting significantly lower survival rates in patients with concomitant EFI and RVI vs those with the single pathologies. Margulis *et al*.^[@CR18]^ confirmed these results by analyzing 419 patients treated for pT3a stage RCC; poorer survival rates were observed in patients with EFI + RVI compared to patients with either pathology alone. Our results indicate a significant difference in RFS among groups A (single pathology) and B (both pathologies), however we did not observe a significant difference among the CSS of the two groups The difference between our study and previous studies is that we excluded patients who had lymph node invasion (LNI)^[@CR10],[@CR16]^. The previous study showed that patients who had EFI and RVI had higher rates of LNI. According to the Da Costa group^[@CR10]^, patients with both pathologies had much higher rates of LNI than those with a single pathology only. A study by Chen *et al*.^[@CR2]^ also showed no difference between RVI and/or EFI among T3N0M0 patients. Findings published by Abel *et al*.^[@CR19]^, showed no difference in CSS according to the presence of RVI with or without EFI. Differences in exclusion criteria showed the somewhat different CSS results between RVI and EFI among our results and previous reported results.

In our results, EFI-only and RVI-only patients had similar RFS and CSS rates. Baccos *et al*.^[@CR11]^ reported that the CSS was similar in RVI-only and EFI-only patients, Novara *et al*.^[@CR17]^, in a large multi-institutional study, showed that an RVI-only group had a better prognosis than the fat-invasion group. In contrast, Jung *et al*.^[@CR20]^ reported that a group of RVI-only patients had lower 2-year and 5-year survival rates than the fat invasion group. Park *et al*.^[@CR16]^ showed that RVI-only patients had significantly lower RFS and CSS than EFI among T3aN0M0 patients after nephrectomy. Therefore, this issue is still controversial and future prospective studies may be required to confirm the results of these studies.

Another interesting issue in this study was shown in multivaratie analysis to predict RFS and CSS. Regardless of the number of factors of pT3a, tumor diameter and tumor necrosis were significant factors to RFS and CSS, respectively. A previous reports also showed in their study among pT3a RCC patients the importance of tumor size in pT3a, HR to recurrence was 1.125 (p \< 0.001)^[@CR21]^ and HR to CSS was 2.506 (p = 0.011)^[@CR2]^, it was same result in our study. And another study about tumor necrosis was similar results to our study, they emphasized the significance of tumor necrosis to prognosis in RCC patients^[@CR22],[@CR23]^.

There were several limitations, in our study. Firstly, our study was a retrospective chart review. Secondly, we could not differentiate between EFI into perinephric fat invasion and sinus fat invasion. However, most studies which compare perinephric fat invasion and sinus fat invasion have reported similar results between two groups. Mouracade *et al*.^[@CR24]^ showed, in their analysis of 143 T3a RCC patients, sinus fat invasion and perinephric fat invasion had similar prognostic values. Poon *et al*.^[@CR25]^ reported that sinus fat invasion was not a predictor of CSS. Therefore, our inability to stratify patients with EFI into perinephric fat invasion and sinus fat invasion groups could be significant. Despite a relatively long follow up duration (mean of roughly 40 months), only 10% patients died from RCC, therefore CSS analysis was limited by the small sample size. More studies with a longer follow up and more patients from multiple centers could overcome this limitation.

In conclusion, among T3aN0M0 RCC patients, those who had both EFI and RVI had poor PFS rates than patients with only one pathology (ie, EFI or RVI). Therefore, following surgery, T3a patients with EFI and RVI should be more closely followed up than other T3a RCC patients.
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